3 of the fund’s new holdings are biotech companies Continue reading...

Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results and Update on Development Programs Conference Call. Please be advised, that today's conference is being recorded.[Operator Instructions]. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the investor section.

Reata Pharmaceuticals Inc (RETA) delivered earnings and revenue surprises of 54.82% and -53.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

As we make our way into the new decade, we’re bound to see some changes take place. However, what’s one constant ready to stand the test of time? Investors seeking out growth.It’s a tried and true fact that potential growth pulls investor focus in as significant gains can translate to massive returns. Having said that, the Wall Street veterans point out that a true monster growth name isn’t just set to make moves in the short-term. Rather, this status can only be earned by stocks racing to new highs through 2020 and beyond. With this in mind, we suited up and set out on our own hunt for the investment opportunities with strong long-term growth narratives. Using the Stock Screener tool from TipRanks, we were able to pinpoint 3 Buy-rated tickers that each boast huge upside potential from current levels. Here’s the lowdown. Reata Pharmaceuticals Inc. (RETA)Reata Pharmaceuticals develops innovative treatments for severe life-threatening diseases that currently don’t have any approved or effective therapy available. Using novel mechanisms of actions, it focuses on small molecule therapeutics. After soaring 269% year-to-date, Wall Street observers are wondering if now’s the time to snap up shares. Attention on RETA has further heightened following a recent positive data readout. On November 11, the company released topline data from the CARDINAL Phase 3 registrational trial of bardoxolone (Bard) for the treatment of Alport syndrome (AS), a genetic condition that causes kidney disease, hearing loss and eye abnormalities. The results indicate that the study’s primary end point as well as key secondary endpoints were met. To top it off, Bard was found to be safe and well-tolerated, with no fluid overload or major adverse cardiac events witnessed.Ladenburg Thalmann & Co. analyst Matthew Kaplan told investors that he was excited by the results as the data clearly showed that the drug improved kidney function. “Based on the positive CARDINAL trial results we believe there is now a greater probability of success for the potential approval of Bard for AS, and we also believe the positive results provide some readthrough to the other CKD indications being pursued with bardoxolone,” he explained. All this good news prompted the four-star analyst to not only keep his Buy rating but also bump up the price target from $239 to $275. (To watch Kaplan’s track record, click here) Meanwhile, Cantor Fitzgerald’s Charles Duncan sees even more gains in store than Kaplan does. Thanks to the data, equity raise and his recent key opinion leader (KOL) diligence, the five-star analyst added $64 to the price target and reiterated the Overweight rating. This new target of $314 puts the potential twelve-month rise at 52%. (To watch Duncan’s track record, click here)The rest of the Street appears to echo the two analysts’ sentiment. Given the 7 Buy ratings and 1 Hold received in the last three months, the word on the Street is that RETA is a Strong Buy. In addition, the $279 average price target suggests 35% upside potential. (See Reata Pharmaceuticals stock analysis on TipRanks) Altice USA Inc. (ATUS)This communications and media company arms its customers with the power of connectivity, offering solutions from high-speed broadband and ultra-HD video to digital advertising solutions, local news, telephony and wireless products. Even though its third quarter earnings results seemed to pose a threat to the growth narrative, some analysts believe that there’s still plenty of room for further gains.When it came to both revenue and EBITDA, ATUS missed the mark due to U.S. Open outage credits. It didn’t help that management guided for a fourth quarter broadband subscriber slowdown as a result of a one-time overlap between an unusual two year back to school promotion from 2017. The outlook for 2019 revenue was also cut. On a positive note, subscriber net additions and losses were in line and stable, respectively, year-over-year, which is a good sign as there were concerns regarding its business and operational support systems (OSS/BSS) transitions.    While Credit Suisse’s Douglas Mitchelson acknowledges that the company’s third quarter was underwhelming, he argues that ATUS is still on track. “Despite the setback, we see accelerating revenue and EBITDA growth as still quite likely on the back of Altice’s mobile launch and fiber-to-the-home rollout, see value to its aggressive levered equity return strategy, and believe there is strong asset value support given cable is a scale business,” he commented. Additionally, he notes that a key area to watch will be the scaling of its mobile segment. This caused the five-star analyst to reaffirm his bullish thesis, leaving the Outperform call and $42 price target unchanged. At $42, the target conveys Mitchelson’s confidence in Altice’s ability to climb 58% higher in the next twelve months. (To watch Mitchelson’s track record, click here)Like Mitchelson, Pivotal Research analyst Jeffrey Wlodarczak remains optimistic. He points to the on-going benefits from data growth and its ability to up-sell consumers to faster tiers as they continue to increase speeds as well as the likely success with its unique wireless MVNO deal as keeping ATUS on an upward trajectory. To this end, the five-star analyst maintained the Buy recommendation and $40 price target. (To watch Wlodarczak’s track record, click here)Turning now to Wall Street, ATUS earns a Moderate Buy analyst consensus based on the 10 Buys and 4 Holds assigned in the last three months. If shares can reach the average price target of $35, a 33% twelve-month gain is on the horizon. (See Altice USA stock analysis on TipRanks)    GCI Liberty Inc. (GLIBA)Also a communications company, GCI Liberty owns and operates a range of businesses including subsidiary GCI as well as has interests in Charter Communications and Liberty Broadband Corporation. On top of its 67% year-to-date increase, one analyst cites its third quarter performance as reflecting a turnaround.Jeffrey Wlodarczak, who also covers GLIBA, believes that the boost to both revenue and earnings came thanks to the end of the negative effects of billing conversions which allowed it to launch new successful products. Not to mention the Pivotal Research analyst also highlights the possible merger or deal with Liberty Broadband as a catalyst that could propel the company forward. A deal can even be seen as a precursor to a merger with Charter. “Post a potential GLIBA/Liberty deal, which would simplify Liberty Media’s cable ownership positions, we continue to expect an eventual RMT with Charter. Such a deal would allow Charter to claw back material rights held by Liberty, simplify the ways for investors to play Charter and allow Charter to acquire an admittedly small GCI asset but with likely material synergies and in-depth knowledge of wireless,” Wlodarczak wrote in a note to clients.He adds, “In the end, if one assumes, as we do, a high likelihood of GLIBA/Liberty/Charter RMT merger there appears to a material amount of additional return from owning GLIBA and Liberty over owning Charter outright.” Bearing this in mind, the five-star analyst tells investors that GCI Liberty is still a good Buy. He didn’t stop there, raising the price target from $75 to $90. Should shares reach this updated target in the next twelve months, the gain would come in at 31%. (To watch Wlodarczak’s track record, click here) Looking at the consensus breakdown, it’s clear that the rest of the Street is in agreement. With 4 Buys compared to no Holds or Sells, the consensus is unanimous: GLIBA is a Strong Buy. While lower than Wlodarczak’s estimate, the $85 average price target indicates respectable upside potential of 23%. (See GCI Liberty stock analysis on TipRanks)

PLANO, Texas, Feb. 12, 2020 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and.

Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of severe, life-threatening diseases, today provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations. The Company announced measures it is taking to protect the health and safety of patients and health care workers involved in ongoing clinical studies of its investigational medicines, as well as its employees and collaborators. Reata conducts clinical studies in many countries around the world that are being impacted by the COVID-19 pandemic.

The last three months have been tough on Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shareholders, who have seen the...

Shares of Reata Pharma skidded Tuesday after the biotech company stopped two clinical tests in part due to the coronavirus pandemic. The drug appeared unlikely to succeed in one test.

Q3 2019 Reata Pharmaceuticals Inc Earnings Call

Reata (RETA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Reata Pharmaceuticals soared Friday on rumors the clinical stage biopharmaceutical company might be acquired by drugmaking giant Amgen . Amgen, meanwhile, was falling 6.2% to $212.29, the worst performer on both the S&P 500 and the Nasdaq, after offering a weaker-than-expected outlook for the year. Investors apparently reacted when Amgen CEO Bob Bradway was discussing kidney medicine during the company's fourth-quarter earnings call.

Q4 2019 Reata Pharmaceuticals Inc Earnings Call

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 30.) * Athersys Inc (NASDAQ: ATHX) (reacted to $7-million capital injection by Japanese partner) * Quidel Corporation (NASDAQ: QDEL)Down In The Dumps (Biotech stocks that hit 52-week lows March 26.) * Gritstone Oncology Inc (NASDAQ: GRTS) * Opko Health Inc. (NASDAQ: OPK) * Second Sight Medical Products Inc (NASDAQ: EYES) (announced winding down of operations in the wake of COVID-19 pandemic) * Trevi Therapeutics Inc (NASDAQ: TRVI)Stocks In Focus Court Rules Against Amarin In Vascepa Litigation Amarin Corporation plc (NASDAQ: AMRN) shares came under pressure after the U.S. District Court for the District of Nevada ruled in favor of two generic companies in the patent litigation brought by Amarin related to its Vascepa capsule franchise.Amarin said the two companies have filed ANDAs -- regulatory filings for approval of a generic drug -- with the FDA for Vascepa. Amarin said it disagrees with the ruling and will pursue all available remedies, including appealing the decision and seeking a preliminary injunction pending appeal, if the ANDAs submitted by the two companies are approved by the FDA.The stock was down 69.66% at $4.12 in Tuesday's premarket session. CytomX Pockets $40M Milestone Payment For Cancer Drug CytomX Therapeutics Inc (NASDAQ: CTMX) said it achieved a clinical milestone related to its CX-2029, a prodrug drug conjugate against CD71, a cell surface protein essential for iron uptake in dividing cells. The milestone relates to achievement of pre-specified criteria for the dose escalation phase of the ongoing Phase 1/2 study, and this has kicked in $40 million in milestone payments to CytomX.CytomX is co-developing CX-2029 with AbbVie Inc (NYSE: ABBV) following a 2016 licensing agreement."CD71 is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient delivery of cytotoxic payloads to tumor cells," CytomX said.Issuing a clinical update in light of the COVID-19 pandemic, CytomX said it has decided to temporarily pause new patient enrollment and new site activation in the study evaluating CX-2009 and has also opted to terminate the study evaluating the anti-PD-L1 Probody CX-072 in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Yervoy in melanoma.CytomX shares were trading 6.72% to $7.15 in Tuesday's premarket session. See also: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty Esperion Commercially Launches Non-Statin LDL-Cholesterol Lowering Drug Esperion Therapeutics Inc (NASDAQ: ESPR) announced commercial availability of its bempedoic acid (brand name Nexletol) tablet, indicated for lowering LDL-cholesterol, in the U.S.The company said the tablet is now available at a list price of around $10 per day to payers.The stock was adding 1.53% to $34.50 in premarket trading Tuesday.Reata Stops Late-Stage Study Of Lead Drug In Hypertension Due To COVID-19 Risk Reata Pharmaceuticals Inc (NASDAQ: RETA) said it has decided, in consultation with Data Safety Monitoring Board, to stop its Phase 3 CATALYST study due to the risk of severe adverse outcomes associated with COVID-19 among patients with respiratory and autoimmune diseases.The study was evaluating its bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension. The company said the decision is not due to any safety issues with the investigational asset.View more earnings on IBBReata said it will also close the RANGER study, an open-label extension study of bardoxolone in patients with PAH. It also temporarily paused enrollment of new patients in the Phase 3 FALCON trial in patients with autosomal dominant polycystic kidney disease.The stock was sliding 9.81% to $146 in premarket trading Tuesday.Savara Stops Enrollment In 2 Cystic Fibrosis Studies Savara Inc (NASDAQ: SVRA) said it is has terminated enrollments into two studies, ENCORE and AVAIL, citing patient safety amid the COVID-19 pandemic.AVAIL is a Phase 3 study evaluating AeroVanc in cystic fibrosis patients, who have methicillin-resistant Staphylococcus aureus lung infection, while ENCORE is a Phase 2a study evaluating Molgradex in nontuberculous mycobacterial lung infection in CF patientsIn premarket trading Tuesday, Savara shares were moving down 7.66% to $2.17.Akero Reports Positive Midstage Results For NASH Drug Akero Therapeutics Inc (NASDAQ: AKRO) announced positive results for the Phase 2a BALANCED study that evaluated three doses of investigational non-alcoholic steatohepatitis, or NASH, therapy AKR-001. The company noted that for all the three doses, the study met the primary endpoint of absolute change from baseline in liver fat as measured by magnetic resonance imaging - proton density fat fraction at week 12.The company said it will report top-line safety/tolerability, lab measures and paired biopsy data from the study in the second quarter.Akero, however, said it is delaying the planned initiation of the BALANCED study cohort C in NASH patients who have compensated cirrhosis, Child-Pugh Class A. Verona Pharma's Inhaled Ensifentrine Found Efficacious In Midstage COPD Study VERONA PHARMA P/S ADR (NASDAQ: VRNA) announced positive efficacy and safety data with a single dose of pressurized metered-dose inhaler formulation of ensifentrine in a Phase 2 study in patients with moderate to severe chronic obstructive pulmonary disease.The company noted that data from the single dose part (Part A) of the study demonstrated a statistically significant and clinically meaningful increase in lung function as measured by forced expiratory volume in one second compared to placebo.Lily Announces Licensing Agreement For Immunometabolic Drugs Eli Lilly And Co (NYSE: LLY) announced a licensing and collaboration agreement with privately held Sitryx to discover and develop immunometabolic medicines. The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.Sitryx stands to receive a $50-million upfront payment and also a $10-million equity investment from Lilly. The former is also eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range.In premarket trading Tuesday, Lilly shares were down 1.76% at $136. Iterum To Delay Late-Stage Readout Of Urinary Tract Infection Drug Iterum Therapeutics PLC (NASDAQ: ITRM) announced a delay in the release of top-line data from the pivotal Phase 3 studies of sulopenem in complicated urinary tract infection and uncomplicated urinary tract infection from the first quarter to early second quarter.Earnings Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported flat fourth-quarter revenue of $1.2 million and a loss of 8 cents per share, narrower than the year-ago loss of 29 cents per share. The loss was in line with expectations.The company also hinted at a possible delay in the European launch of buprenorphine implant, its novel six-month maintenance treatment for opioid use disorder, as its commercialization partner Molteni is located in Italy.The stock was seen shedding 9.52% to 25 cents in premarket trading Tuesday.Alpine Immune Sciences Inc (NASDAQ: ALPN) reported fourth-quarter collaboration revenue of $884,000 in 2019 compared to zero revenue a year ago. The net loss per share narrowed from 80 cents to 33 cents. Analysts estimated a wider loss of 58 cents per share.In premarket trading, Alpine shares were rallying 22.57% to $3.15. On The Radar Earnings * Trinity Biotech plc (NASDAQ: TRIB) (before the market open) * I-Mab ADR (NASDAQ: IMAB) (before the market open) * China Pharma Holdings, Inc. (NYSE: CPHI) (before the market open) * Milestone Scientific Inc. (NYSE: MLSS (before the market open) * BioNTech SE - ADR (NASDAQ: BNTX) (time not supplied)Related Link: COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama See more from Benzinga * The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance * The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

PLANO, Texas, May 11, 2020 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced.

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

PLANO, Texas, Feb. 19, 2020 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced.

PLANO, Texas, May 04, 2020 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and.

Shares of Reata Pharmaceuticals jumped Friday on reports suggesting Amgen could be interested in acquiring the smaller biotech company. Reata is working on a key kidney disease treatment.